Astria Therapeutics (NASDAQ:ATXS) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Astria Therapeutics (NASDAQ:ATXSGet Rating) from a hold rating to a sell rating in a report published on Friday morning, Zacks.com reports.

According to Zacks, “Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company’s program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics, formerly known as Catabasis Pharmaceuticals Inc., is based in BOSTON. “

Separately, HC Wainwright reissued a buy rating and issued a $13.00 price target on shares of Astria Therapeutics in a report on Friday, March 11th.

Shares of Astria Therapeutics stock traded up $0.07 on Friday, reaching $4.10. The stock had a trading volume of 12,866 shares, compared to its average volume of 10,705. Astria Therapeutics has a 1 year low of $3.83 and a 1 year high of $15.72. The business’s 50 day moving average is $6.27 and its two-hundred day moving average is $6.07.

Astria Therapeutics (NASDAQ:ATXSGet Rating) last announced its quarterly earnings results on Thursday, March 10th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). On average, sell-side analysts predict that Astria Therapeutics will post -2.99 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG purchased a new stake in Astria Therapeutics in the third quarter valued at approximately $27,000. Morgan Stanley purchased a new stake in Astria Therapeutics in the third quarter valued at approximately $28,000. Millennium Management LLC purchased a new stake in Astria Therapeutics in the fourth quarter valued at approximately $55,000. Goldman Sachs Group Inc. bought a new position in Astria Therapeutics during the third quarter valued at approximately $99,000. Finally, Oppenheimer & Co. Inc. bought a new position in Astria Therapeutics during the third quarter valued at approximately $108,000. 51.79% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics (Get Rating)

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.

Recommended Stories

Get a free copy of the Zacks research report on Astria Therapeutics (ATXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.